Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Эффективная и безопасная профилактика тромбообразования
Мелехов А.В., Борисов С.Н. Эффективная и безопасная профилактика тромбообразования. Consilium Medicum. 2013; 15 (5): 88–92.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Nichols M, Townsend N et al. European cardiovascular disease statistics, fourth edition. 2012.
2. Roger VL, Go AS, Lloyd-Jones DM et al. Executive summary: heart disease and stroke statistics – 2012 update: a report from the American Heart Association. Circulation 2012; 125 (1): 188–97.
3. Харченко В.И., Какорина Е.П. Смертность от болезней системы кровообращения в России. Необходимость усиления кардиологической службы и модернизации медицинской статистики в РФ. Рос. кардиол. журн. 2009; 2.
4. Оганов Р.Г., Калинина А.М., Концевая А.В. Экономический ущерб от сердечно-сосудистых заболеваний в Российской Федерации. Кардиоваск. терапия и профилактика. 2011; 4: 4–9.
5. Gawaz M. Blood platelets – clinical relevance. Stuttgart: Georg Thieme Verlag 2010.
6. Schrör K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 1997; 23 (4): 349–56.
7. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330 (18): 1287–94.
8. Patrono C, Baigent C, Hirsh J, Roth G. American College of Chest Physicians. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133
(Suppl. 6): 199–233.
9. Riepe MW, Kasischke K, Raupach A. Acetylsalicylic acid increases tolerance against hypoxic and chemical hypoxia. Stroke 1997; 28 (10): 2006–11.
10. Kumar A, Vishvakarma NK, Tyagi A et al. Anti-neoplastic action of aspirin against a T-cell lymphoma involves an alteration in the tumour microenvironment and regulation of tumour cell survival. Biosci Rep 2012; 32 (1): 91–104.
11. Khaidakov M, Szwedo J, Mitra S et al. Antiangiogenic and antimitotic effects of aspirin in hypoxia–reoxygenation modulation of the LOX-1-NADPH oxidase axis as a potential mechanism. J Cardiovasc Pharmacol 2010; 56 (6): 635–41.
12. Baigent C, Collins R, Appleby P et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ 1998; 316 (7141): 1337–43.
13. Wallentin LC. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden. J Am Coll Cardiol 1991; 18 (7): 1587–93.
14. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group. Lancet 1990; 336 (8719): 827–30.
15. Juul-Möller S, Edvardsson N, Jahnmatz B et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992; 340 (8833): 1421–5.
2. Roger VL, Go AS, Lloyd-Jones DM et al. Executive summary: heart disease and stroke statistics – 2012 update: a report from the American Heart Association. Circulation 2012; 125 (1): 188–97.
3. Харченко В.И., Какорина Е.П. Смертность от болезней системы кровообращения в России. Необходимость усиления кардиологической службы и модернизации медицинской статистики в РФ. Рос. кардиол. журн. 2009; 2.
4. Оганов Р.Г., Калинина А.М., Концевая А.В. Экономический ущерб от сердечно-сосудистых заболеваний в Российской Федерации. Кардиоваск. терапия и профилактика. 2011; 4: 4–9.
5. Gawaz M. Blood platelets – clinical relevance. Stuttgart: Georg Thieme Verlag 2010.
6. Schrör K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 1997; 23 (4): 349–56.
7. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330 (18): 1287–94.
8. Patrono C, Baigent C, Hirsh J, Roth G. American College of Chest Physicians. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133
(Suppl. 6): 199–233.
9. Riepe MW, Kasischke K, Raupach A. Acetylsalicylic acid increases tolerance against hypoxic and chemical hypoxia. Stroke 1997; 28 (10): 2006–11.
10. Kumar A, Vishvakarma NK, Tyagi A et al. Anti-neoplastic action of aspirin against a T-cell lymphoma involves an alteration in the tumour microenvironment and regulation of tumour cell survival. Biosci Rep 2012; 32 (1): 91–104.
11. Khaidakov M, Szwedo J, Mitra S et al. Antiangiogenic and antimitotic effects of aspirin in hypoxia–reoxygenation modulation of the LOX-1-NADPH oxidase axis as a potential mechanism. J Cardiovasc Pharmacol 2010; 56 (6): 635–41.
12. Baigent C, Collins R, Appleby P et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ 1998; 316 (7141): 1337–43.
13. Wallentin LC. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden. J Am Coll Cardiol 1991; 18 (7): 1587–93.
14. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group. Lancet 1990; 336 (8719): 827–30.
15. Juul-Möller S, Edvardsson N, Jahnmatz B et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992; 340 (8833): 1421–5.
Авторы
А.В.Мелехов, С.Н.Борисов
ГБОУ ВПО Российский научно-исследовательский медицинский университет им. Н.И.Пирогова Минздрава РФ, Москва;
Кафедра госпитальной терапии №2 ГКБ №12, Москва
ГБОУ ВПО Российский научно-исследовательский медицинский университет им. Н.И.Пирогова Минздрава РФ, Москва;
Кафедра госпитальной терапии №2 ГКБ №12, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.